InvestorsHub Logo
Followers 45
Posts 2321
Boards Moderated 0
Alias Born 09/28/2009

Re: None

Thursday, 06/11/2015 10:22:09 AM

Thursday, June 11, 2015 10:22:09 AM

Post# of 1253
NEWS POSTED ON SCOTTRADE Roth Capital initiated coverage on Plasmatech Biopharmaceuticals Inc (NASDAQ: PTBI) with a Buy rating. The target price for Plasmatech is set to $16. Plasmatech shares have dropped 55.81 percent over the past 52 weeks, while the S&P 500 index has surged 9.07 percent in the same period. Plasmatech shares rose 12.45 percent to $7.95 in pre-market trading. View More Analyst Ratings for PTBIView the Latest Analyst Ratings Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga PRO: http://pro.benzinga.com 2015 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserved. Acquire Media
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABEO News